


# KCI EXUDATE Management Pathway



Nil to Low	Moist	Moderate	Highly
<p><b>KERRALITE COOL™ DRESSINGS</b></p> <p><b>Soothing, debriding and moisture-balancing dressing</b></p> <ul style="list-style-type: none"> <li>• Effective debridement of devitalised tissue<sup>1</sup></li> <li>• Reduced risk of maceration<sup>2</sup></li> <li>• Excellent fluid management properties<sup>2</sup></li> <li>• A significant reduction in pain<sup>2</sup></li> </ul>	<p><b>KERRACEL™ DRESSINGS</b></p> <p><b>Gelling fibre dressing</b></p> <ul style="list-style-type: none"> <li>• Highly absorbent, gel forming dressing that retains integrity upon removal<sup>3</sup></li> <li>• Helps maintain wounds moisture balance</li> <li>• Locks in exudate to protect peri wound skin from maceration<sup>4</sup></li> </ul>	<p><b>KERRAFOAM™ GENTLE BORDER DRESSING</b></p> <p><b>Moisture managing, gentle silicone bordered dressing</b></p> <ul style="list-style-type: none"> <li>• Unique wicking layer distributes exudate across the whole width of dressing, helping to prevent maceration<sup>5</sup></li> <li>• EXUSAFE™ Technology locks away exudate, bacteria and MMPs, even under compression.<sup>6,7*</sup></li> <li>• Achieves effective fluid management</li> </ul>	<p><b>KERRAMAX CARE™ DRESSINGS</b></p> <p><b>Superabsorbent dressing</b></p> <ul style="list-style-type: none"> <li>• High absorbency and retention<sup>8</sup></li> <li>• EXUSAFE™ Technology locks away potentially harmful bacteria and MMPs<sup>11</sup></li> <li>• Unique wicking layer distributes exudate throughout the dressing evenly<sup>9</sup></li> <li>• Highly conformable allowing the dressing to be folded for variety of different wounds<sup>11</sup></li> </ul>

## CONSIDER OTHER PRIORITIES:



Delicate Skin	Odour	Infection	Has the wound stalled?
<p><b>ADAPTIC TOUCH™ DRESSING</b></p> <p><b>Silicone wound contact layer dressing</b></p> <ul style="list-style-type: none"> <li>• Flexible, open-mesh silicone structure</li> <li>• Minimizes pain and trauma at dressing removal<sup>12</sup></li> <li>• Allows free passage of exudate<sup>13</sup></li> <li>• Prevent adherence of the secondary dressing</li> </ul>	<p><b>ACTISORB™ SILVER 220 DRESSING</b></p> <p><b>Activated charcoal and silver dressing</b></p> <ul style="list-style-type: none"> <li>• The dressing traps odour in the dressing and binds bacteria and toxins that impair the healing process<sup>14,*</sup></li> <li>• Silver kills the bacteria in the dressing<sup>15,*</sup></li> </ul>	<p>PLEASE REFER TO: <b>INFECTION PATHWAY</b></p>	<p><b>PROMOGRAN™ MATRIX</b></p> <p><b>Collagen/ORC primary wound dressing</b></p> <p><b>Wounds not infected with delayed healing and without overt signs of infection:</b></p> <ul style="list-style-type: none"> <li>• Reduces inflammatory markers and stimulates granulation tissue<sup>16</sup></li> <li>• Binds excess inflammatory proteases, protects growth factors and lowers pH<sup>17</sup></li> <li>• Clinically proven to shorten a patients stay in hospital<sup>16</sup></li> <li>• Significantly reduces wound size<sup>16</sup></li> </ul> <p><b>PROMOGRAN PRISMA™ MATRIX</b></p> <p><b>Collagen/ORC/Silver-ORC primary wound dressing</b></p> <p><b>Wounds at risk of infection:</b></p> <ul style="list-style-type: none"> <li>• Reduces inflammatory markers and stimulates granulation tissue<sup>16</sup></li> <li>• Protects growth factors and lowers pH<sup>17</sup></li> <li>• Contains ionically bound silver, a well-known antimicrobial agent</li> <li>• Significantly reduces in vitro Pseudomonas aeruginosa biofilm population and activity of bacterial proteases<sup>18,*</sup></li> </ul>

\*As demonstrated *in-vitro*. Specific indications, contraindications, warnings, precautions and safety information may exist for Systagenix, Crawford and KCI (Acclity companies) products. Please consult a healthcare provider and product instructions for use prior to application. This material is intended for healthcare professionals.

References: 1. Williams-Kelly W. KerraLite Cool for the debridement of a painful leg ulcer. Poster presented at: Wounds UK Annual Conference; November 13-15, 2017; Harrogate, UK. 2. Irwins N. Evaluation of the mode of action of a new gel wound dressing. Wounds UK. 2014;10(2): 3. Lovett J, Jackson S, Stephenson C. Assessment of dressing integrity using an Ex-Vivo porcine cavity wound model. Knutsford, UK: Crawford Healthcare; 2017. 4. Abaka-Wood R. A series to analyse KerraCel, Aquacel Extra and Durafiber samples - RGD Trial report CHC R189 (in vitro). Knutsford, UK: Crawford Healthcare; 2014. 5. Glover D, Clark M., Wound management using a superabsorbent foam dressing: outcomes of a post-CE-mark primary care clinical evaluation. Wounds UK, September 2015; Volume 11; Issue 3; Page 78-86. 6. Cardiff Metropolitan University. An investigation into the ability of KerraMax Care and KerraFoam to bind bacteria - RGD Trial report CHC R752. Knutsford, UK: Crawford Healthcare; 2013. 7. Perfectus Biomed. Crawford 006 Report. Knutsford, UK: Crawford Healthcare; 2015. 8. Byrne C. Lab performance evaluation of silicone adhesive foam suppliers (bordered and non-bordered) - RGD Trial report CHC R614. Knutsford, UK: Crawford Healthcare; 2017. 9. McIntyre W. Absorbency, retention under compression, and absorbency under compression testing of KERRAMAX CARE™ against market competitors - RGD Trial Report CHC R821. Knutsford, UK: Crawford Healthcare; 2019. 10. Cochrane, C.A. Evaluation of matrix metalloproteinases by wound care products. University of Liverpool, UK. July 2011. 11. Lovett J. CHC R564 Assessment of conformable KerraMax Care samples provided by Finesse. Knutsford, UK: Crawford Healthcare; 2011. 12. International case series: Using Adaptic Touch™ non-adhering silicone dressing, case studies. Wounds International. London; 2013. 13. Stephens S, Mistry P, Del Bono M, et al. Evaluation of the free passage of fluid through a non-adhering silicone wound contact layer (in vitro). Poster presented at: Wounds UK Annual Conference; November 15-17, 2010; Harrogate, UK. 14. Nisbet L et al. The benefits of activated charcoal cloth with silver on odour control and bacterial endotoxin binding. Poster presented at: Wounds UK Annual Conference; November 14-16, 2011; Harrogate, United Kingdom. 15. Remison et al. Antimicrobial efficacy of silver impregnated activated charcoal wound dressing. Poster presented at: ETBS; September 21-23, 2003; Amsterdam, NL. 16. Vin F. The healing properties of Promogran in venous leg ulcers. Journal of Wound Care. 2002;11(9): 17. Holmes C, Wrobel J, MacEachern M et al. Collagen-based wound dressings for the treatment of diabetes-related foot ulcers: a systematic review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013; 6:17-29. 18. Bourdillon K, Delury C and Cullen B. Biofilms and delayed healing – an in vitro evaluation of silver and iodine-containing dressings and their effect on bacterial and human cells. International Wound Journal. 2017;14(6):1066-1075.

Copyright 2019 KCI Licensing, Inc. All rights reserved. Unless otherwise noted, all trademarks designated herein are proprietary to KCI Licensing, Inc., Systagenix Wound Management, Ltd., or Crawford Healthcare, Ltd. PRA-PM-UK-00147 (11/19)